ABIONYX Pharma Secures Funding to Advance Sepsis Treatment

ABIONYX Pharma is set to expand its operations following the successful approval of all resolutions in its recent Combined General Meeting. With a strategic financing round raising up to €33 million, the company now has financial visibility through 2028, supporting its key objectives.

The funds will primarily facilitate the launch of a pivotal Phase 2b clinical trial for CER-001, a promising treatment for sepsis, expected to start by the end of 2026. In parallel, ABIONYX is working on marketing authorization for CER-001 in LCAT deficiency, targeting submission to the EMA by early 2028.

ABIONYX remains focused on executing its strategic goals, including clinical and manufacturing timelines, and furthering its recombinant apoA-I-based platform. Collaborations with academic and industrial partners will be key to accelerating commercialization efforts.